Updated COVID-19 Vaccine Adverse Event Profiles from VAERS

39.9 KB Excel file contains processed adverse event case reports for COVID-19 vaccines from the VAERS system. The data supports an updated analysis of safety trends for Pfizer-BioNTech, Moderna, Janssen, bivalent, and Novavax vaccines through June 2024. It includes stratified analyses by age and sex, and AE classification using the Ontology of Adverse Events.

Use Cases

• Compare adverse event profiles, such as thrombosis, myocarditis, and Guillain-Barré syndrome, across vaccine types like monovalent and bivalent formulations.
• Analyze age-stratified patterns using reported bimodal distributions in children aged 0–9 and adults aged 50–69.
• Investigate sex differences in AE reporting, where females report more common AEs and males are linked to serious AEs like cardiovascular events.
• Perform ontology-based classification to categorize significant adverse events within a structured hierarchy for enhanced interpretation.

Strengths

• Data covers multiple vaccine types, including monovalent, bivalent mRNA, recombinant vector, and protein subunit vaccines.
• Analysis includes temporal coverage through 28 June 2024, capturing evolving safety trends.
• Stratified analyses provide insights by age group and sex for specific AE patterns.

Limitations

• Small file size of 39.9 KB indicates limited scope, likely containing summary or processed results rather than raw case-level data.
• Unknown row and column counts prevent assessment of dataset scale and feature completeness.
• Relies on processed VAERS data, which is a passive reporting system subject to under-reporting and reporting biases.

Provenance

Source

Vaccine Adverse Event Reporting System (VAERS), processed via Cov19VaxKB.

Collection Method

Systematic analysis of AE profiles using Pearson’s Chi-square test, proportional reporting ratios, and case report frequencies.

Time Range

2020 to 28 June 2024.

Freshness

Last updated March 2026, with data through June 2024.

Geography

null